Clinical Trials
6 trialsNCT00412880 2022-06-22
BI 2536 Second Line Monotherapy in SCLC
Boehringer Ingelheim
Phase 2 Completed
NCT00376623 2022-06-21
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00710710 2022-05-04
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00701766 2014-05-16
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
Boehringer Ingelheim
Phase 2 Completed
NCT00706498 2014-05-16
Phase II Study of BI 2536 in Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00526149 2013-10-07
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed